Marvell Technology shares surged 4.6% in morning trading to $290.62, driven by an onslaught of bullish analyst commentary released ahead of the session. The most consequential note came from UBS, which boosted its price target to $340 from $230 while keeping a Buy rating and substantially upgrading the company’s outlook tied to CXL interconnects in AI data centers.
UBS now projects the global market for CXL-related ASIC attach will expand to between $7 billion and $10 billion by 2030. Within that opportunity set, the bank views Marvell as the current market share leader and expects the company to generate roughly $1 billion in CXL-specific revenue in 2027, primarily from XPU-attach programs with two major U.S. hyperscalers. UBS forecasts that figure could rise to about $2 billion in 2028.
The firm also raised its broader Marvell revenue estimates to $16.8 billion for 2027 and $23.9 billion for 2028, figures that reflect UBS’s upgraded view of Marvell’s role in the CXL ecosystem. These revised projections were accompanied by the firm’s maintained Buy recommendation.
Adding further validation, Cantor Fitzgerald analyst C.J. Muse increased his firm’s price target to $300 from $220 but maintained a Neutral rating. That move signaled that even more cautious Street voices are adjusting valuations upward as Marvell’s fundamental picture brightens.
The wider market provided a mildly positive backdrop for the move, with the Nasdaq up 0.6% and the S&P 500 higher by 0.3% on the session. Marvell’s advance substantially outpaced these index gains, indicating that company-specific catalysts were the primary drivers of the stock’s performance.
Market commentary around the AI semiconductor sector more broadly cited sustained hyperscaler capital expenditure commitments as a supporting force. Peers named as beneficiaries of CXL adoption include Broadcom and Astera Labs; however, analysts continue to portray Marvell as the current market share leader for the technology.
Investors also had recent company-level signals to consider. CEO Matt Murphy had previously provided guidance pointing to roughly 35% year-over-year revenue growth in the second quarter, and Marvell reported an all-time high pipeline encompassing more than 50 custom AI chip design opportunities. Those operational indicators, combined with significantly higher analyst price targets, helped validate investor demand for the shares.
In intraday trading the stock reached an intraday high of $292.16 before easing back modestly later in the session.
Market context:
- Shares rose 4.6% to $290.62 in morning trading.
- UBS raised its price target to $340 from $230 and kept a Buy rating.
- UBS projects $1 billion of CXL-specific revenue for Marvell in 2027 and about $2 billion in 2028.
- Cantor Fitzgerald raised its target to $300 from $220 with a Neutral rating.